Last updated on July 2019

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors


Brief description of study

To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.

Clinical Study Identifier: NCT03811652

Find a site near you

Start Over

Research Site

Heidelberg, Australia
6.96miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.